| Protocol No. | Title |
|---|---|
| 23-MYEL-21-RG | REGN5458 compared Elotuzumab, Pomalidomide and Dexamethasone in Pts w/ R/R Multi-Myeloma. |
| 24-GU-84-MSD | 24-GU-84-MSD (003-00):A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy |
| 24-GU-85-MSD | 24-GU-85-MSD (004-00): A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next generation Hormonal Agent (NHA) |
| 24-LEUK-25-KO-PMC | Study to Investigate the Safety and Tolerability of Ziftomenib in Combo w/ Ven/Aza, Ven, or 7+3, AML |
| NCI-CIRB-EA2222 | Therapy w/ or w/o Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases |